Therapeutic innovations in inflammatory bowel diseases.
Leuven, Belgium. In Clin Pharmacol Ther, Jan 2016
In this review, we highlight the emerging new classes of IBD therapeutics under clinical evaluation and their method of action, including JAK inhibitors, anti-SMAD7 oligonucleotides, and cell-based therapies.
Progress in corneal wound healing.
Los Angeles, United States. In Prog Retin Eye Res, Nov 2015
Successful surgical ways of replacing the diseased endothelium have been clinically tested, and new approaches to accelerate endothelial healing and suppress endothelial-mesenchymal transformation have been proposed including Rho kinase (ROCK) inhibitor eye drops and gene therapy to activate TGF-β inhibitor SMAD7.
Next-Generation Therapeutics for IBD.
Amsterdam, Netherlands. In Curr Gastroenterol Rep, Jun 2015
Other therapeuticals that might find their way to the market the coming years include the anti-mucosal vascular addressin cell adhesion molecule (MAdCAM) PF-00547659, small molecules (including laquinimod and the CCR9 antagonist Vercirnon), as well as an orally active SMAD7 antisense oligonucleotide that showed clinical benefit in Crohn's disease patients.
Analysis of differentially expressed genes based on microarray data of glioma.
Nanjing, China. In Int J Clin Exp Med, 2014
In addition, the transcription factor analysis showed these DEGs were regulated by the binding sites of transcription factors GLI2, SP1, SMAD7, SMAD3, RELA, STAT5B, CTNNB1, STAT5A, TFAP2A and SP3.